• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

9.930 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 193,946
Open 9.930
Bid (Size) 8.710 (500)
Ask (Size) 8.840 (2,100)
Prev. Close 9.930
Today's Range 9.930 - 9.930
52wk Range 3.920 - 19.14
Shares Outstanding 101,102,152
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Which stocks are experiencing notable movement on Thursday? ↗
May 07, 2026
Via Chartmill
Top stock movements in today's session. ↗
May 07, 2026
Via Chartmill

Performance

YTD
-44.1%
-44.1%
1 Month
+110.8%
+110.8%
3 Month
+120.2%
+120.2%
6 Month
-16.0%
-16.0%
1 Year
+36.8%
+36.8%

More News

Read More
There are notable gap-ups and gap-downs in today's session. ↗
May 07, 2026
Via Chartmill
Which stocks are moving before the opening bell on Thursday? ↗
May 07, 2026
Via Chartmill
News headline image
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel
May 07, 2026
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit
May 05, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
May 05, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 05, 2026
From Schall Law
Via GlobeNewswire
News headline image
ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
May 02, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 01, 2026
From Schall Law
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit
April 28, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
April 28, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 28, 2026
From Schall Law
Via GlobeNewswire
News headline image
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
April 25, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 24, 2026
From Schall Law
Via GlobeNewswire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
April 21, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 21, 2026
From Schall Law
Via GlobeNewswire
News headline image
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
April 18, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit
April 17, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 17, 2026
From Schall Law
Via GlobeNewswire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
April 14, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 14, 2026
From Schall Law
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit
April 10, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 10, 2026
From Schall Law
Via GlobeNewswire
News headline image
ATRA INVESTOR REMINDER: Atara Biotherapeutics, Inc. Investors Have Until May 22, 2026 To Seek Lead Plaintiff Role
April 07, 2026
From Kirby McInerney LLP
Via GlobeNewswire

Frequently Asked Questions

Is Atara Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Atara Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Atara Biotherapeutics, Inc. - Common Stock trade on?
Atara Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Atara Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Atara Biotherapeutics, Inc. - Common Stock is ATRA on the Nasdaq Stock Market
What is the current price of Atara Biotherapeutics, Inc. - Common Stock?
The current price of Atara Biotherapeutics, Inc. - Common Stock is 9.930
When was Atara Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Atara Biotherapeutics, Inc. - Common Stock was at 05/07/26 04:00 PM ET
What is the market capitalization of Atara Biotherapeutics, Inc. - Common Stock?
The market capitalization of Atara Biotherapeutics, Inc. - Common Stock is 1.00B
How many shares of Atara Biotherapeutics, Inc. - Common Stock are outstanding?
Atara Biotherapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap